NCT03869762 2024-09-25
DICE
Cancer Trials Ireland
Phase 2 Terminated
Clinical Trials
10 trialsNCT03382574 2022-06-14
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
National Cancer Institute (NCI)
Phase EARLY_PHASE1 Terminated
NCT03408652 2021-10-22
MOSCAR
Centre Leon Berard
Phase 3 Terminated
NCT01077154 2021-09-28
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Amgen
Phase 3 Terminated
NCT03620149 2021-01-06
REDUCE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT01545648 2020-01-02
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
University of California, San Francisco
Phase 2 Terminated
NCT01952054 2019-11-22
Denosumab for Breast Cancer With Bone Mets
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02758132 2019-11-08
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
University of Hawaii
Phase 2 Terminated
NCT01864798 2018-11-27
D-Beyond
Jules Bordet Institute
Phase 2 Terminated
NCT03070002 2018-11-20
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
Northwestern University
Phase 2 Terminated